Plasminogen activator uPA is a direct transcriptional target of the JAG1-notch receptor signaling pathway in breast cancer

Cancer Research

Volumn 71, Issue 1, 2011, Pages 277-286

  Shimizu, Mamiko ^a   Cohen, Brenda ^a   Goldvasser, Pavel ^a   Berman, Hal ^a,b   Virtanen, Carl ^c   Reedijk, Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CBF 1 PROTEIN; DNA BINDING PROTEIN; JAGGED1; NOTCH RECEPTOR; PLASMINOGEN ACTIVATOR; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BINDING SITE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78651388566     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2523     Document Type: Article

References (42)

1. American Cancer Society. Cancer facts and figures. Atlanta; 2009.
2. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008;45:31-45.
3. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004;5:348-52.
4. Nichols JT, Miyamoto A, Weinmaster G. Notch signaling-constantly on the move. Traffic 2007;8:959-69.
5. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004;9:145-63.
6. Imatani A, Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000;19:223-31.
7. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008;68:5226-35.
8. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006;66:1517-25.
9. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-86.
10. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21.
11. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007;20:685-93.
12. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
13. Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008;111:439-48.
14. Farnie G, Clarke RB. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 2007;3:169-75.
15. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15:4649-64.
16. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 2010;121:53-64.
17. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
18. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004;20:1453-4.
19. Saldanha AJ. Java Treeview-extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.
20. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
21. Park JT, Shih Ie M, Wang TL. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 2008;68:8852-60.
22. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63.
23. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008;10:R97.
24. Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 2010;123:113-24.
25. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009;15:68-74.
26. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008;108:191-201.
27. Nellesen DT, Lai EC, Posakony JW. Discrete enhancer elements mediate selective responsiveness of enhancer of split complex genes to common transcriptional activators. Dev Biol 1999;213:33-53.
28. Guan E, Wang J, Laborda J, Norcross M, Baeuerle PA, Hoffman T. T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells. J Exp Med 1996;183:2025-32.
29. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998;18:2077-88.
30. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Downregulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
31. Hansen SK, Nerlov C, Zabel U, Verde P, Johnsen M, Baeuerle PA, et al. A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. Embo J 1992;11:205-13.
32. Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA 2006;103:9262-7.
33. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-48.
34. Hildenbrand R, Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 2009;34:15-23.
35. Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, et al. Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res 2009;15:452-9.
36. Pang RT, Leung CO, Ye TM, Liu W, Chiu PC, Lam KK, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010;31: 1037-44.
37. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991;6:1583-92.
38. Pew T, Zou M, Brickley DR, Conzen SD. Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway. Endocrinology 2008;149:2637-45.
39. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
40. Krop IE, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, et al. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 2006;24:10574.
41. Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Curr Mol Med 2006;6:275-89.
42. Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 2006;7:87-97.